There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evolus Inc (NASDAQ:EOLS) and Obalon Therapeutics Inc (NASDAQ:OBLN) with bullish sentiments.
Evolus Inc (EOLS)
In a report released today, Louise Chen from Cantor Fitzgerald maintained a Buy rating on Evolus Inc, with a price target of $35. The company’s shares opened today at $18.31.
Chen said:
“. Post a solid quarter of execution, we are reiterating our OW rating and 12-month price target of $35. We think DWP-450’s value proposition is underappreciated and that it will pick up more market share than anticipated. Therefore, the upcoming approval of DWP-450 and other potential catalysts should drive EOLS shares higher, in our view.”
According to TipRanks.com, Chen has currently no stars on a ranking scale of 0-5 stars, with an average return of -6.3% and a 40.2% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Melinta Therapeutics Inc, and Aclaris Therapeutics Inc.
Currently, the analyst consensus on Evolus Inc is a Moderate Buy with an average price target of $31, representing a 69.3% upside. In a report issued on July 19, Mizuho Securities also reiterated a Buy rating on the stock with a $27 price target.
.
See today’s analyst top recommended stocks >>
Obalon Therapeutics Inc (OBLN)
In a report released today, Kyle Rose from Canaccord Genuity maintained a Buy rating on Obalon Therapeutics Inc, with a price target of $2.50. The company’s shares opened today at $1.68, close to its 52-week low of $1.46.
According to TipRanks.com, Rose is a 4-star analyst with an average return of 11.1% and a 53.3% success rate. Rose covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Smith & Nephew Snats, and Stryker Corporation.
Currently, the analyst consensus on Obalon Therapeutics Inc is a Moderate Buy with an average price target of $5.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
